Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-cell Acute Lymphoblastic Leukemia: A Registry-Based Study by the EBMT Acute Leukemia Working Party

Author:

Cheikh Jean El1ORCID,Ngoya Maud,Galimard Jacques-EmmanuelORCID,Remenyi P2,Kulagin Alexander3ORCID,Aljurf Mahmoud D4ORCID,Bahar Babak5,Wu Depei6,Arat Mutlu7ORCID,Salmenniemi Urpu8,CASTILLA-LLORENTE Cristina9,Socie Gerard10ORCID,Helbig Grzegorz11,schroeder thomas12,Sakellari Ioanna13,Rambaldi Alessandro14,Carpenter Benjamin15,labussiere helene16,Stelljes Matthias17,Brissot Eolia18ORCID,giebel s19,Peric Zinaida20ORCID,Nagler Arnon21,Ciceri Fabio22ORCID,Bazarbachi Ali23,Mohty Mohamad24ORCID,Busca Alessandro25ORCID

Affiliation:

1. aubmc

2. Istvan & St. Laszlo Hospital

3. RM Gorbacheva Research Institute, Pavlov University

4. King Faisal Specialist Hospital & Research Center

5. Tehran University of Medical Sciences

6. The First Affiliated Hospital of Soochow University

7. Istanbul Florence Nightingale Hospital

8. University of Turku

9. Gustave Roussy Cancer Campus

10. Assistance Publique des Hopitaux de Paris, Saint Louis hospital

11. Medical University of Silesia

12. University Hospital Essen

13. George Papanikolaou Hospital

14. ASST Papa Giovanni XXIII

15. University College London Hopsital

16. Centre Hospitalier Lyon Sud

17. University of Muenster

18. Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire

19. unknown

20. University Hospital Zagreb

21. Chaim Sheba Medical Center

22. San Raffaele Scientific Institute

23. American University of Beirut Medical Center

24. Hôpital St Antoine, Sorbonne University, INSERM UMRs 938

25. AOU Citta' della Salute e della Scienza

Abstract

Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Methods Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. Results The median age at transplant was 33.4 years (18.1–75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). A later year of HSCT was associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). Conclusion This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting.

Publisher

Research Square Platform LLC

Reference27 articles.

1. T-cell acute lymphoblastic leukemia;Raetz EA;Hematol Am Soc Hematol Educ Program,2016

2. Diagnosis and Subclassification of Acute Lymphoblastic Leukemia;Chiaretti S;Mediterr J Hematol Infect Dis,2014

3. Molecular subsets and prognostic factors in acute lymphoblastic leukemia;Westbrook CA;Leukemia,1997

4. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia - PubMed [Internet]. [cited 2023 May 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/28821272/

5. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study;Trinquand A;J Clin Oncol Off J Am Soc Clin Oncol,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3